ZEJULA 200 mg/1 (Niraparib TABLET, FILM COATED) 200 mg/1

ZEJULA 200 mg tablets are a prescription medication used for specific therapeutic purposes. This film-coated tablet is manufactured by GlaxoSmithKline LLC in the USA.

Strength

200 mg/1

Pack Size

30 TABLET, FILM COATED in 1 BOTTLE (0173-0912-13)

Manufacturer / TM Owner

GlaxoSmithKline LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ZEJULA is primarily used in the management of certain types of cancer. It is often prescribed for patients who have specific genetic markers or mutations. The medication works by targeting particular enzymes involved in DNA repair, which can help in controlling the growth of cancer cells. Patients should consult their healthcare provider to determine if ZEJULA is suitable for their condition.

Side Effects

Common effects of ZEJULA may include fatigue, nausea, and anemia. Some patients might experience vomiting, constipation, or thrombocytopenia. It is important to monitor for any unusual symptoms and report them to a healthcare professional.

Precautions & Warnings

ZEJULA should be handled with care and stored as directed. It is essential to follow the prescribed dosage and administration instructions provided by a healthcare provider. Patients should inform their doctor about any other medications they are taking to avoid potential interactions.

Avoid Interactions

ZEJULA may interact with certain medications, including strong CYP3A inhibitors and inducers. It is important to discuss all current medications with a healthcare provider to ensure safe and effective use. Alcohol and other substances may also affect the efficacy of ZEJULA.

References

Frequently Asked Questions

ZEJULA is used in the treatment of certain types of cancer, particularly in patients with specific genetic markers.

ZEJULA is taken orally, typically as a film-coated tablet. Follow the specific instructions provided by your healthcare provider.

Common side effects may include fatigue, nausea, anemia, vomiting, constipation, and thrombocytopenia.

ZEJULA may interact with certain medications, so it is important to consult a healthcare provider before combining it with other drugs.

ZEJULA is manufactured by GlaxoSmithKline LLC in the USA.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.